The currently available therapies for Alzheimer's disease (AD) and related forms of dementia are limited by modest efficacy, adverse side effects, and the fact that they do not prevent the relentless progression of the illness. The purpose of the studies described here was to investigate the neuroprotective effects of the nicotine metabolite cotinine as well as a small series of cotinine and nicotine analogs (including stereoisomers) and to compare their effects to the four clinically prescribed AD therapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027973 | PMC |
| http://dx.doi.org/10.1016/j.bmcl.2014.02.008 | DOI Listing |
Publication Analysis
Top Keywords
alzheimer's disease
8
evaluation nicotine
4
nicotine cotinine
4
cotinine analogs
4
analogs potential
4
potential neuroprotective
4
neuroprotective agents
4
agents alzheimer's
4
disease currently
4
currently therapies
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!